BIOCRYST PHARMACEUTICALS, INC. Operating Lease Right-of-Use Assets
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Operating Lease Right-of-Use Assets of $7.55 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-02-26
- 2025-12-31: Operating Lease, Right-of-Use Asset $7.55M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $7.72M.
- 2025-06-30: Operating Lease, Right-of-Use Asset $7.92M.
- 2025-03-31: Operating Lease, Right-of-Use Asset $7.89M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2025-12-31 | $7.55M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $7.72M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $7.92M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $7.89M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $8.06M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $8.34M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $8.54M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $8.86M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $8.68M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $11.38M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $6.95M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $7.05M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $4.24M 10-K · filed 2024-02-27 | $6.81M 10-K · filed 2023-02-27 |
| 2022-09-30 | $6.80M 10-Q · filed 2022-11-04 | |
| 2021-12-31 | $6.47M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $5.19M 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |